The Association between Progression of Atherosclerosis and the Methylated Amino Acids Asymmetric Dimethylarginine and Trimethyllysine by Løland, Kjetil Halvorsen et al.
The Association between Progression of Atherosclerosis
and the Methylated Amino Acids Asymmetric
Dimethylarginine and Trimethyllysine
Kjetil H. Løland1*, Øyvind Bleie2, Heidi Borgeraas3, Elin Strand1, Per M. Ueland1, Asbjørn Svardal1,
Jan E. Nordrehaug1,2, Ottar Nyga˚rd1,2
1Department of Clinical Science, University of Bergen, Bergen, Norway, 2Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, 3Morbid Obesity
Centre, Vestfold Hospital Trust, Tønsberg, Norway
Abstract
Objective: We previously showed that treatment with folic acid (FA)/B12 was associated with more rapid progression of
coronary artery disease (CAD). High doses of FA may induce methylation by increasing the availability of S-adenosyl-
methionine (SAM). Asymmetric dimethylarginine (ADMA) and trimethyllysine (TML) are both produced through proteolytic
release following post-translational SAM–dependent methylation of precursor amino acid. ADMA has previously been
associated with CAD. We investigated if plasma levels of ADMA and TML were associated with progression of CAD as
measured by quantitative coronary angiography (QCA).
Methods: 183 patients from the Western Norway B Vitamin Intervention Trial (WENBIT) undergoing percutaneous coronary
intervention (PCI) were randomized to daily treatment with 0.8 mg FA/0.4 mg B12 with and without 40 mg B6, B6 alone or
placebo. Coronary angiograms and plasma samples of ADMA and TML were obtained at both baseline and follow-up
(median 10.5 months). The primary end-point was progression of CAD as measured by diameter stenosis (DS) evaluated by
linear quantile mixed models.
Results: A total of 309 coronary lesions not treated with PCI were identified. At follow-up median (95% CI) DS increased by
18.35 (5.22–31.49) percentage points per mmol/L ADMA increase (p-value 0.006) and 2.47 (0.37–4.58) percentage points per
mmol/L TML increase (p-value 0.021) in multivariate modeling. Treatment with FA/B12 (6B6) was not associated with ADMA
or TML levels.
Conclusion: In patients with established CAD, baseline ADMA and TML was associated with angiographic progression of
CAD. However, neither ADMA nor TML levels were altered by treatment with FA/B12 (6B6).
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Introduction
Hyperhomocysteinemia is a significant risk factor for coronary
artery disease (CAD) in epidemiological studies. However, several
large-scale clinical trials with homocysteine-lowering B-vitamins
have repeatedly demonstrated no clinical benefit of the interven-
tion. [1–3] On the contrary, pooled analyses suggest increased
cardiovascular mortality associated with B-vitamin treatment in
certain sub-groups [2] as well as increased cancer incidence and
all-cause mortality. [4] We have previously shown that a sub-
group of patients with established CAD had a more rapid
progression of sub-clinical atherosclerosis as measured by quan-
titative coronary angiography (QCA), when receiving 0.8 mg folic
acid (FA) and 0.4 mg vitamin B12 daily. [5] FA and vitamin B12
supplementation promotes remethylation of homocysteine to
methionine and subsequently increases S-adenosyl-methionine
(SAM), which is the main methyl donor in cellular transmethyl-
ation reactions. [6].
A growing body of evidence has shown that both global and
site-specific hypo- and hypermethylation of DNA and histones are
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associated with cardiovascular disease (CVD). [6] High doses of
FA induce aberrant DNA methylation in some [7] but not all
studies. [8] It has been speculated that the lack of cardiovascular
protective effect of homocysteine-lowering FA supplementation is
due to a simultaneously increased methylation potential and
subsequent epigenetic alterations of gene expression by folate. [9]
Histone methylation is limited to the e-amino groups of amino
acid residues in the form of mono-, di- or trimethylation, [6] and
only two amino acids in histones undergo methylation, i.e.
arginine and lysine. [10].
Asymmetric dimethylarginine (ADMA), a product of proteolytic
degradation of methylated proteins such as histones, is a well-
known inhibitor of nitric oxide synthase (NOS) and has been
associated with endothelial dysfunction and CVD. [11–14]
ADMA levels have not, to our knowledge, been linked to global
methylation status. 6-N-trimethyllysine (TML), a precursor in
carnitine synthesis, [15,16] is another methylated amino acid
which is produced through the lysosomal or proteasomal
degradation of proteins such as histones containing methylated
amino acids residues, specifically trimethylated lysine. [16].
We investigated whether ADMA and TML could serve as
predictive markers of progression of CAD as measured by QCA
and if treatment with FA-vitamin B12 is related to ADMA or TML
levels.
Methods
Study Design and Patient Population
The current study included patients who participated in the
Western Norway B Vitamin Intervention Trial (WENBIT).
WENBIT was a double-blinded, placebo-controlled, two-centre
trial conducted among 3090 adult patients (20.5% women) having
undergone coronary angiography for suspected CAD. Details,
inclusion and exclusion criteria, and the main results of the trial
have been described previously [1] In order to simultaneously
evaluate the effect of FA/vitamin B12 and vitamin B6, patients
were randomly assigned into 4 groups, using 2 by 2 factorial
design, to daily receiving an oral capsule with one of the following
compositions: 1) FA 0.8 mg, vitamin B12 (cyanocobalamin) 0.4 mg
and vitamin B6 (pyridoxine) 40 mg, or 2) FA plus vitamin B12, or
3) vitamin B6, or 4) placebo. In this study we evaluated the effect of
FA/vitamin B12 on plasma levels of ADMA and TML.
Intervention groups 1) and 2) were thus compared to 3) and 4)
in the subsequent analyses.
In the current sub-study, patients at high risk of procedural
complications, or those presenting with a baseline coronary
anatomy of such a nature that re-angiography probably would
prove unsuccessful, were also excluded. Further exclusion criteria
were baseline and/or follow-up coronary angiograms considered
unsuitable for quantitative analysis.
At Haukeland University Hospital a total of 570 patients
underwent percutaneous coronary intervention (PCI) following the
baseline angiography during the sub-study inclusion time period
and were eligible for re-angiography, of which 371 (65%)
underwent re-angiography as previously described. [5] A total of
23 (6%) participants were excluded from the analysis due to
technically inadequate angiograms and 165 (47%) participants did
not fulfill QCA lesion criteria. We included 183 patients with
adequate serial QCA data who had at least one qualifying lesion,
resulting in a total of 309 coronary lesions for analyses.
Ethics Statement
All clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki. Written
informed consent was obtained from all WENBIT participants,
and an additional written informed consent was collected from
patients scheduled for re-angiography. Both WENBIT and the
current sub-study were approved by the Regional Committee for
Medical and Health Research Ethics (Regional Ethics Committee
[REC] West/Regional Etisk Komite´ [REK] vest, which is the
institutional review board available at http://helseforskning.
etikkom.no), the Norwegian Medicines Agency (Legemiddelverket)
and by the Data Inspectorate (Datatilsynet). WENBIT was
registered with ClinicalTrials.gov with identifier NCT00354081
and URL http://www.clinicaltrials.gov/ct2/show/NCT00354081.
WENBIT was a two-centre study conducted at Haukeland
University Hospital, Bergen, and Stavanger University Hospital,
Stavanger, both located in western Norway. All clinical research
was conducted in Norway and was subject to Norwegian law.
Quantitative Coronary Angiography
Both baseline and follow-up coronary angiograms were
analysed using QCA by two trained technicians blinded to the
treatment regimen and supervised by an experienced interven-
tional cardiologist. A total of 16 coronary artery segments were
evaluated in all patients; i.e. 15 segments as per the American
Heart Association standardization criteria, [17] plus the right
atrioventricular branch. Eligible lesions for analysis had a
reference diameter $2 mm, diameter reduction of $30% at
either baseline or follow-up, and were adequately visualized at
similar projections at both procedures. The analysed segment had
not been treated with PCI. Cases of disagreement between the
observers, about eligibility of a certain lesion, were subject to
reanalyses by both observers. Following all QCA procedures,
segments from both observers were compared to ensure equality
concerning accurate numbering of segments, the correct angio-
gram analysed, and the actual stenosis portrayed.
Lesions were analysed using digitalized QCA (Quantcor QCA
[CAAS II V 5.0], Pie Medical Imaging, the Netherlands). An end-
diastolic frame showing the stenosis without foreshortening or
vessel overlap, and free of intra-coronary wires, was selected. If the
stenosis differed in severity in different projections, the projection
demonstrating the most severe stenosis was subject to analysis. The
contrast-filled tip of the catheter was used for calibration, and
computer-defined obstruction analysis without manual contour
correction was used where applicable. However, ostial stenoses
required the use of manually-defined obstruction analysis (user-
defined reference vessel diameter and stenosis length), while
branched artery segment required manual correction of vessel
contour.
Follow-up and End-point
The primary measure for each selected lesion was diameter
stenosis (DS) [18,19] in percentages, measured as continuous
variables and defined as the mean of the values measured
separately by two different observers.
When all baseline and follow-up lesions had been analysed by
both observers, the inter-observer difference in DS was calculated.
The 10% of lesions with the largest difference were subject to re-
analysis.
The primary angiographic end-point of the study was defined as
DS measured at follow-up, while baseline values were used for
adjustment. I.e. change in DS was the de facto end-point.
Blood Samples
Blood samples were collected at baseline and at the re-
angiography. Routine blood analyses such as hematologic
parameters, renal function markers and lipid-related factors were
ADMA, TML and Progression of CAD
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Table 1. Baseline Characteristics and Laboratory Findings in Patients with Angiographic Coronary Lesions (n = 183).
Characteristics
Group 1 (n = 98)
FA, B12±B6
Group 2 (n = 85)
Placebo or B6 P-value
Demographic characteristics
Age - years 59.3 (10.5) 61.5 (9.4) 0.14
Female sex - no. (%) 17 (17.3) 12 (14.1) 0.69
Clinical characteristics
Systolic Blood Pressure - mmHg 138.3 (20.7) 147.4 (23.9) 0.01
Body Mass Index - m2/kg 27.0 (3.2) 27.2 (3.5) 0.79
Ejection Fraction - %a 60.7 (7.4) 61.6 (9.2) 0.45
Cardiovascular risk factors - no. (%)
Stable angina at baseline angiography 67 (68.4) 59 (69.4) 0.88
NSTACS at presentation 31 (31.6) 26 (30.6) 0.88
Extracardial vascular diseaseb 7 (7.1) 15 (17.6) 0.03
Prior AMI 24 (24.5) 26 (30.6) 0.36
Prior PCI 22 (22.4) 12 (14.1) 0.15
Prior CABG 5 (5.1) 1 (1.2) 0.14
Hypercholesterolaemia 58 (59.2) 58 (68.2) 0.20
Hypertension 40 (40.8) 40 (57.6) 0.40
Diabetes Mellitus (type I and II) 7 (7.1) 10 (11.8) 0.28
Current smoker 34 (34.7) 27 (31.8) 0.68
Disease severity 0.90
1-vessel disease 36 (36.7) 31 (36.5) 1.00
2-vessel disease 41 (41.8) 38 (44.7) 0.77
3-vessel disease 21 (21.4) 16 (18.8) 0.71
Medical therapyc - no. (%)
Statins 98 (100.0) 81 (95.2) 0.03
b-adrenergic receptor antagonists 82 (83.7) 57 (67.0) 0.01
Calcium antagonists 18 (18.4) 11 (12.9) 0.32
ACE-inhibitorsd 12 (12.2) 19 (22.4) 0.07
Acetylsalisylic acid 96 (98.0) 85 (100.0) 0.19
ADP receptor antagonists 92 (93.9) 79 (92.9) 0.80
Laboratory findings
S-C-Reactive Protein - mg/L 1.8 (4.9) 2.5 (4.9) 0.40
S-LDL cholesterol - mmol/L 3.0 (1.3) 3.1 (1.1) 0.39
S-HDL cholesterol - mmol/L 1.2 (0.4) 1.2 (0.4) 0.76
Apolipoprotein B100 - g/L 0.87 (0.34) 0.88 (0.28) 0.33
eGFR – mL/min/1.73 m2 95 (17) 93 (19) 0.34
Serum glucose - mmol/L 5.5 (1.3) 5.7 (1.7) 0.72
Plasma -homocysteine - mmol/L 9.9 (3.1) 9.8 (3.3) 0.27
Plasma folate - nmol/L 10.1 (5.8) 11.0 (6.3) 0.20
Asymmetric dimethylarginine - mmol/L 0.50 (0.09 0.52 (0.12) 0.23
S-Trimethyllysine - mmol/L 0.85 (0.34) 0.87 (0.40) 0.48
Carnitine – mmol/L 40.5 (7.5) 41.0 (10.1) 0.52
c-Butyrobetaine – mmol/L 0.98 (0.30) 1.02 (0.28) 0.05
For continuous variables, mean and standard deviation or median and interquartile range within each group is calculated. Student’s T-test or Mann-Withney U-test was
used to compare the two groups. For categorical variables, number and percentage is presentend and a Chi square test was used to compare the four groups. Fisher’s
exact test was used when appropriate. All biochemical parameteres are prestented as median (interquartile range). FA, folic acid (0.8 mg); B12, vitamin B12 (0.4 mg); B6,
vitamin B6 (40 mg); PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; NSTACS, composite syndrom consisting of acute coronary
syndrome including both ST-elevated and non-ST-elevated myocardial infarction; AMI, acute myocardial infarction; CHD, coronary heart disease; LMS, left main stem;
LAD, left anterior descending artery; CX, circumflex branch; RCA, right coronary artery; ACE, Angiotensin I converting enzyme; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; eGFR, estimated glomerular filtration rate; ADMA, asymmetric dimethylarginine. Percentages may not add up due to rounding of numbers.
aEjection fraction was measured during ventriculography for the majority of the patients. When this was not performed, ultrasonic echocardiography was used.
bA prior diagnosis of any peripheral or cerebrovascular disease.
cMedication at discharge.
dIncluding ARB - angiotensin receptor blockers.
doi:10.1371/journal.pone.0064774.t001
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analysed in fresh samples at the Laboratory of Clinical Biochem-
istry, Haukeland University Hospital, by standard methods, all
blinded to study end-points and randomization. Blood samples for
measurements of ADMA, B vitamins and associated compounds
were analysed at the laboratory of Bevital AS (www.bevital.no),
Bergen, Norway using methods previously described. [20] Plasma
TML, free carnitine and c-butyrobetaine were analysed using
MS/MS as described previously [21] with some modifications of
the high-performance liquid chromatography (HPLC) conditions.
Estimation of glomerular filtration (eGFR) rate was done using the
simplified MDRD-equation. [22].
Statistical Analysis
Analyses were conducted according to the intention-to-treat
principle. Continuous variables are reported as means 6 SD or as
median (interquartile range) where appropriate. Categorical
variables are presented as numbers (percentages).
Differences between intervention groups in continuous variables
were analysed using Student’s t-test or Mann Whitney U-test.
Differences in categorical variables were analysed by chi-square
test or Fisher’s exact test. Inter-observer reliability were assessed
on QCA measurements by calculating the average measure intra-
class coefficient [23]. The intra-class correlation coefficient (ICC)
of ADMA and TML was calculated using samples one year apart
and subjects were considered as random effects (‘‘oneway’’ model).
Degree of correlation between covariates was assessed using
Spearman’s rank correlation coefficient.
In order to assess for non-linear relationships between outcome
and explanatory variables, we first fitted a generalized additive
mixed model (data not shown). A linear relationship provided the
best model fit, thus we proceeded to use a simpler linear model.
As several lesions stemmed from the same patients – i.e. 309
lesions from 183 patients, our data was not independent. We have
previously addressed this problem using a mixed effects model
allowing for random effects. [5].
Because of non-normal distributions we used a non-parametric
test, i.e. conditional quantile regression (CQR). CQR is the
estimation of an unknown quantile of an outcome as a function of
a set of covariates where the response is assumed to follow an
asymmetrical Laplace distribution and using a likelihood-based
approach. [24] Bootstrapping is used to estimate the variance of
the covariates.
We estimated the median DS as a function of fixed and random
effects using a linear quantile mixed model (LQMM). A total of
three models were fitted, i.e. two bivariate models with baseline
measurement of ADMA or TML and DS as explanatory variables
and a multivariate model which in addition included baseline
measurements of age, gender, FA/B12 intervention status (yes/no),
follow-up time (days), diabetes (yes/no), current smoking (yes/no),
systolic blood pressure (mmHg), body mass index (kg/m2), eGFR
(mL/min/1.73 m2), apolipoprotein B100 (g/L) and C-reactive
protein (mg/L). Estimation of the 10th, 25th, 50th (median), 75th
and 90th percentile was performed for all models.
Using a similar LQMM, we assessed the effect of FA/vitamin
B12 supplementation on measurements of ADMA or TML at
follow-up as outcome variable and ADMA or TML at baseline
and FA/vitamin B12 randomization status as explanatory
variables. The clustering of coronary segments within lesions was
the random effect.
LQMM was applied using the lqmm package [25] in R version
2.15.0 (R Development Core Team; Vienna, Austria), imple-
mented as described by Geraci and Bottai. [24] Intra-class
correlation coefficients were calculated using the R package, irr
version 0.84. For all analyses, a p-value ,0.05 was considered
statistically significant.
Table 2. Baseline Angiographic Characteristics of the 309 Coronary Lesions (from n= 183 patients).
Characteristic
Group 1 (n = 152)
FA, B12±B6
Group 2 (n = 157)
Placebo or B6 P Value
Selection - no. (%)
Included coronary lesions 152 (49.2) 157 (50.8) 2
Patients 98 (53.6) 85 (46.4) 2
LMS lesions 2 (1.3) 1 (0.6) 0.62
LAD lesions 38 (25.0) 31 (19.7) 0.33
CX lesions 34 (22.4) 48 (30.6) 0.13
RCA lesions 78 (51.3) 77 (49.0) 0.78
Analysed segment morphology
Length analysed segment - mm 21.0 (7.2) 21.4 (6.5) 0.58
Length stenotic segment - mm 10.2 (4.2) 10.1 (4.3) 0.80
Reference diamenter - mm 3.09 (0.82) 3.08 (0.69) 0.89
Minimum lumen area - mm2 4.16 (2.76) 3.95 (2.26) 0.45
Volume stenosis - mm3 29.3 (11.9) 29.9 (11.9) 0.66
Minimum lumen diameter - mm 1.94 (0.61) 1.90 (0.49) 0.51
Diamenter stenosis - % 37.2 (9.7) 38.0 (9.6) 0.47
For continuous variables, mean and standard deviation within each group is calculated. Student’s T-test was used to compare the two groups. For categorical variables,
number and percentage is presentend and a Chi square test used to compare the two groups. Fisher’s exact test was used when appropriate. ). FA, folic acid (0.8 mg);
B12, vitamin B12 (0.4 mg); B6, vitamin B6 (40 mg); LMS, left main stem artery; LAD, left anterior descending artery; CX; circumflex artery; RCA, right coronary artery; mm,
millimeters.
doi:10.1371/journal.pone.0064774.t002
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Results
Baseline Characteristics
Baseline demographic, clinical and laboratory characteristics
(Table 1) showed higher systolic blood pressure, more extracardial
disease as well as less statin and betablocker use in the B6/placebo
group. Ninety-eight percent of the patients were treated with
statins. Median (interquartile range [IQR]) age was 60.0 (14.0)
years, 15.8% were women and 27.3% of the patients had a history
of prior myocardial infarction. Median (IQR) serum total
cholesterol was 5.0 (1.3) mmol/L, serum triglycerides 1.54 (0.87)
mmol/L and serum CRP 2.0 (4.9) g/L. The median (IQR)
concentrations were 0.51 (0.11) mmol/L for ADMA, 0.86 (0.36)
mmol/L for TML and 10.3 (6.0) nmol/L for folate.
Angiographic Findings
A total of 309 coronary lesions from 183 patients were finally
identified by both observers to comply with the criteria for DS
analysis, and angiographic characteristics are shown in table 2. We
observed progression of CAD during follow-up as indicated by a
statistically significant change in DS. Among 309 lesions median
(95% CI) DS increased by 3.51 (2.26–4.76) percentage points
(p,0.0001).
Angiographic Progression According to Plasma
Asymmetric Dimethylarginine and Trimethyllysine
The main results are shown in table 3 as well as figure 1. Plasma
levels of ADMA at baseline were, in the bivariate model,
significantly related to DS at follow-up. Median (95% CI) DS
increased by 14.57 (1.79–27.35) percentage points per mmol/L
increase of ADMA (p-value 0.026). A similar statistically significant
Figure 1. Asymmetric dimethylarginine, trimethyllysine and angiographic progression of coronary artery disease. The graph shows
the regression line from a linear quantile mixed model. The two left panels show the relation between the asymmetric dimethylarginine (ADMA) and
DS measured at follow-up, whereas the two right panels show the relation between trimethyllysine (TML) and DS at follow-up. The bivariate models
(adjusted for baseline DS measurement) are on the top and the multivariate (adjusted for age, sex, folic acid/B12 intervention status, follow-up time,
diabetes, smoking, systolic blood pressure, body mass index, estimated glomerular filtration rate (eGFR), apolipoprotein B100, C-reactive protein,
ADMA or TML) at the bottom. The plasma level of either ADMA or TML is shown on the x-axis, with DS at follow-up on the y-axis. The solid line
represents the regression line for the effect on median DS, while the others are displayed according to the legend.
doi:10.1371/journal.pone.0064774.g001
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effect was found in the 25th percentile of DS, while in the 10th, 75th
and 90th percentile of DS there was non-significant relation to
ADMA.
Plasma TML at baseline was statistically significantly related to
DS at follow-up in the bivariate model at the 10th percentile of DS,
which increased by 3.11 (0.64–5.58) percentage point per mmol/L
increase of TML (p-value 0.01). At the 25th, median, 75th and 90th
percentile of DS there was non-significant relation to TML.
In the multivariate model both ADMA and TML at baseline
was independently associated with DS at follow-up (Table 3). The
median DS increased by 18.35 (5.22–31.49) percentage points per
mmol/L increase of ADMA (p-value 0.006) and 2.47 (0.37–4.58)
percentage points per mmol/L increase of TML (p-value 0.021).
ADMA was significantly related to the 10th, 25th, 75th and 90th
percentile of DS, while TML was not. In addition, male gender,
C-reactive protein and eGFR were significantly related to DS.
Inclusion of eGFR in the multivariate model increased both the
estimates and level of significance for both ADMA and TML
regarding estimation of DS. When adjusting for c-butyrobetaine
or carnitine in the multivariate model, no significant change to the
ADMA or TML estimates or levels of significance occurred (data
not shown). In separate analyses without inclusion of ADMA or
TML, neither c-butyrobetaine nor carnitine predicted DS in bi- or
multivariate analysis.
At baseline, the mean (SD) length of the included lesions was
21.2 (6.8) mm with a reference diameter of 3.08 (0.75) mm,
minimum lumen diameter 1.92 (0.55) mm while DS was 37.6 (9.6)
%.
Assessment of Correlation between Covariates
At baseline Spearman’s ranks correlation coefficient between
ADMA and TML was 0.27 (p-value ,0.0001). ADMA showed
the following correlation coefficients with other covariates: c-
butyrobetaine 0.29 (p-value ,0.0001), carnitine 0.08 (p-value
0.15), creatinine 0.17 (p-value 0.003) and eGFR 20.35 (p-value
,0.0001). TML significantly correlated (all p-value ,0.0001) with
c-butyrobetaine, carnitine, creatinine and eGFR with a correla-
tion coefficient of 0.41, 0.22, 0.28 and 20.26 respectively.
In addition, c-butyrobetaine correlated with carnitine 0.42 (p-
value,0.0001), eGFR 0.42 (p-value,0.0001) and creatinine 0.54
(p-value ,0.0001). Carnitine did not significantly correlate with
eGFR (0.08; p-value 0.14) or creatinine (0.01; p-value 0.80).
Asymmetric Dimethylarginine and Trimethyllysine
According to B Vitamin Supplementation
Cumulative distribution frequency plots showing the differences
in ADMA and TML between baseline and follow-up during the B-
vitamin treatment are shown in figure 2 for both intervention
groups. By visual inspection there was no apparent difference
between baseline and follow-up measurements of neither ADMA
nor TML levels between the two treatment groups. In LQMM,
FA/vitamin B12 treatment did not result in a statistically significant
change in ADMA levels for the 25th, median, 75th or 90th
percentile. The 10th percentile of ADMA did however increase
with 0.040 (0.002–0.078) mmol/L in patients receiving FA/vitamin
B12 (p-value 0.04). No percentile (10
th, 25th, median, 75th or 90th)
of TML was altered by FA/vitamin B12 treatment. Vitamin B6
treatment did not alter either ADMA or TML levels (data not
shown).
Intra-individual Stability of Biomarkers
Repeated measurements of ADMA and TML were available.
One-way intra-class correlation coefficient (ICC) was 0.54 (95%
CI 0.43–0.64) for ADMA and 0.37 (95% CI 0.24–0.49) for TML.
Patient Follow-up
Patients were followed for median (IQR) 316 (78) days. At sub-
study end, patients assigned to FA/vitamin B12 had lowered
homocysteine levels by 24.8% whereas patients receiving vitamin
B6 alone or placebo had unchanged homocysteine levels compared
to baseline).
Table 3. Diameter stenosis at follow-up according to plasma concentrations of asymmetric dimethylarginine and trimethyllysinea.
Independent
variable Effect estimates for each variable according to modeled percentile of diameter stenosis at follow-up
b
10th (31.5% DS) 25th (35.0% DS)
Median [50th]
(40.0% DS) 75th (47.0% DS) 90th (55.5% DS)
Bivariate ADMA modelc
ADMA at baseline -
mmol/L
9.63 (25.92–25.19) 0.22 14.63 (0.94–28.32) 0.04 14.57 (1.79–17.35) 0.03 1.81 (215.77–19.40) 0.84 5.04 (222.12–32.19)0.71
Bivariate TML modeld
TML at baseline -
mmol/L
3.11 (0.64–5.58) 0.01 2.19 (20.22–4.60) 0.07 1.68 (20.15–3.52) 0.07 1.00 (22.35–4.34) 0.56 0.78 (24.32–5.89) 0.76
Multivariate modee
ADMA – mmol/L 24.25 (7.40–41.10) ,0.01 19.75 (5.76–33.74) ,0.01 18.35 (5.22–31.49) ,0.01 19.93 (5.14–34.73) ,0.01 22.07 (6.50–37.65) ,0.01
TML – mmol/L 1.81 (20.99–4.61) 0.20 1.73 (20.74–4.20) 0.17 2.47 (0.37–4.58) 0.02 2.09 (20.69–4.87) 0.14 2.72 (21.12–6.55) 0.16
DS, Diameter Stenosis; ADMA, asymmetric dimethylarginine; TML, trimethyllysine.
aNon-parametric linear quantile mixed-effects models of diameter stenosis at follow-up using Laplace distribution.
bEffect estimate given as regression coefficient (95% confidence interval) and p-value for change in percentage point diameter stenosis.
cThe fixed effect in this model is ADMA and DS measured at baseline while the random effect is the clustering of arterial segments within a single patient. Estimates are
presented as median (95% confidence interval). Standard error is estimated using bootstrapping.
dThe fixed effect in this model is TML and DS measured at baseline while the random effect is the clustering of arterial segments within a single patient. Estimates are
presented as median (95% confidence interval). Standard error is estimated using bootstrapping.
eThe fixed effect in this model is DS measured at baseline, follow-up time in days, presence of diabetes, randomization (folic acid/B12 vs no folic acid/B12) status at
baseline, plasma TML at baseline, smoking status, age, gender, plasma ADMA at baseline, systolic blood pressure, body mass index, kidney function, apolioprotein B100
and C-reactive protein while the random effect is the clustering of arterial segments within a single patient. Standard error is estimated using bootstrapping.
doi:10.1371/journal.pone.0064774.t003
ADMA, TML and Progression of CAD
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e64774
Discussion
In the current substudy of a large randomized clinical trial with
moderate doses of oral FA and vitamin B12 we followed 183
patients treated with PCI for angiographic progression of CAD in
non-treated lesions for a median of 10.5 months. A total of 309
coronary artery lesions as well as plasma levels of ADMA and
TML were evaluated at both baseline and follow-up. Baseline
levels of ADMA and TML was however independently associated
with angiographic progression of CAD as measured by DS at
follow-up in multivariate statistical models, with ADMA showing
the strongest relationship. FA/vitamin B12 supplementation did
not alter median ADMA or TML at follow-up.
In accordance with previous studies we found ADMA to be
associated with increased risk of CVD, [11–14] an effect mainly
thought to be mediated through inhibition of NOS and
subsequent endothelial dysfunction. [11] ADMA was indepen-
dently associated with angiographic progression of CAD over a
wide distribution of DS using a multivariate model – i.e. the
adverse effect of elevated ADMA was similar in respect to both the
effect estimate and level of significance across the 10th, 25th, 50th,
75th and 90th percentile of DS. To our knowledge this association
has not previously been shown for de novo atherosclerosis.
Like ADMA, TML is produced through post-translational
methylation of amino acids in nuclear proteins [16] and
subsequent release through proteolysis; yet associations of TML
with CVD have not been addressed. Both previous speculations
[9] and emerging evidence [6,26,27] suggest that epigenetic
alterations of chromatin is relevant to the development and
progression of atherosclerosis. Plasma levels of TML, in our
material, were associated with angiographic progression of disease
Figure 2. Asymmetric dimethylarginine and trimethyllysine before and after supplementation with folic acid/vitamin B12. The graph
shows empirical cumulative distribution frequencies for asymmetric dimethylarginine on the left and trimethyllysine on the right. Patients receiving
folic acid/B12 are displayed on the top, while patients receiving placebo or B6 on the bottom. Time of measurement is shown as baseline (solid line)
and follow-up (dashed line) after a median of 10.5 month.
doi:10.1371/journal.pone.0064774.g002
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when we studied median DS in a multivariate model, but the effect
was only borderline statistically significant in a bivariate model. In
contrast to ADMA, TML levels is most likely dependent upon
kidney function because TML availability is probably the rate-
dependent step in carnitine biosynthesis, or at least TML
clearance. [15,28] Inclusion of eGFR in our multivariate models
did however not substantially alter the TML effect; neither did
inclusion of carnitine precursor c-butyrobetaine or carnitine,
suggesting that the observed association between TML and CAD
progression is not confounded by neither kidney function nor
metabolites of carnitine biosynthesis. Accordingly, carnitine
metabolites did not predict CAD progression in a separate
analysis.
While the adverse CVD-consequence of ADMA has been
linked to NO inhibition, there is no indication that TML acts by a
similar mechanism. It is known that FA supplementation increases
the availability of SAM and it has recently been shown that FA
supplementation induces aberrant DNA methylation in vitro [7]
Increased SAM, induced by FA, may enhance methylation of
histones, but data supporting such effects have not been published.
Histone methylation can be either mono-, di- or trimethylated, all
of which can alter gene expression. [6] Since di- and trimethylated
histones are precursors for ADMA and TML respectively, one
could speculate if levels of ADMA and TML reflect global histone
hypermethylation.
While we have previously reported a possible detrimental effect
of FA treatment in a sub-group of patients, [5] we were unable to
prove an association between treatment with FA/vitamin B12 and
plasma levels of either TML or ADMA. Thus, this observation
does not substantiate a possible relationship between histone
hypermethylation and plasma levels ADMA or TML.
Because QCA is a lumenogram, it provides no coronary plaque
information, for which intravascular ultrasound imaging or optical
coherence tomography would be appropriate. However, QCA is
considered an accurate method of measuring progression or
regression of coronary atherosclerosis over time [29] as well as
being a reliable predictor of in-trial and post-trial clinical events
[18,19,30] and in some respect possibly superior to intravascular
ultrasound imaging. [31] Another limitation is the lack of data on
global DNA or histone methylation status which makes us unable
to conclude whether TML or ADMA reflect enhanced methyl-
ation during supplementation with FA. While FA has shown to
induce DNA hypermethylation, [7] effect on histone methylation
following treatment with FA has not been reported.
Our study is amongst the larger studies using QCA
[18,19,32,33]. By performing all QCA analyses twice by 2
technicians and averaging the results, the precision of data
analysis was increased. DS was chosen as the appropriate variable,
since it, in contrast to minimum lumen diameter, is a relative
measurement, thus reducing any potential calibration errors
between the baseline and follow-up angiograms. In addition the
statistical methods applied allow us to reduce the number of data
assumptions. Mixed effects modeling was applied to adjust for the
intra-patient correlation between coronary artery lesions, and
quantile regression was used to enable non-parametric model
allowing for untransformed data without having to assume
normality; both methods leading to greater statistical robustness.
[24] LQMM also allowed us to model the entire distribution of the
outcome variable presenting a more total and unselected view of
the data and illuminating any possible tail effects. [34] The modest
ICCs of 0.37 for TML and 0.54 for ADMA, may be related to
strict metabolic regulation [35] and the influence of life-style
factors such as diet and physical activity on plasma levels. Since
risk estimates based single measurements tends to underestimate
the true effect due to regression dilution one could suspect that the
‘‘true’’ relationships of ADMA and TML with DS are even
stronger. [36].
In this prospective study of patients with established CAD both
ADMA and TML was significantly and independently associated
with angiographic progression of CAD in multivariate statistical
models, although with a slight asymmetrical effect for TML and
with ADMA showing the strongest relationship. However,
moderate doses of FA and vitamin B12 did not alter the plasma
levels of ADMA or TML except those in the lower 10th percentile
of ADMA. Since degradation of methylated proteins such as
histones is the sole source of TML and ADMA, one could
speculate whether ADMA and TML are markers of global histone
methylation. Further investigation should aim at identifying
(lifestyle) determinants of plasma TML, effect on cardiovascular
end-points and whether TML levels modify the effect of B-vitamin
treatment.
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